Imatinib Mesylate (Gleevec)

December, 2004. Essential Inventions is seeking a non-exclusive compulsory license to authorize any qualified entity to manufacture and distribute Glivec (a medication for certain rare cancers) to any country that qualifies under the provisions of Canadian Bill C-9. Below are the relevent documents Essential Inventions' CEO, Terry Gardiner.

December 17, 2004. Letter to Dr. Rodrigo Salinas, Director, Instituto de Salud Publica De Chile. Available as a PDF file in either English or Spanish.

December 14, 2004. Letter to Canadian Health Minister Ujjal Dosanjh requesting a compulsory license.